Policy & Regulation
Adlai Nortye establishes new Scientific Advisory Board
8 March 2021 -

Adlai Nortye, a global clinical-stage biopharmaceutical company, has established its new Scientific Advisory Board (SAB), it was reported on Sunday.

The SAB includes Ronald M Evans, PhD, Tony Hunter, PhD, Jason Pontin, Andrew Zhu, MD, PhD and Wenle Xia, MD.

Dr Ronald M Evans is a Member of the US National Academy of Sciences, Professor at the Salk Institute, Director of the Salk's Gene Expression Laboratory, and March of Dimes Chair in Molecular and Developmental Biology.

Dr Hunter is serving as a member of the US National Academy of Sciences, professor of Molecular and Cell Biology at the Salk Institute and the Renato Dulbecco chair in Cancer Biology.

Pontin is serving as a venture capitalist, angel investor, science and technology writer, and former senior partner at Flagship Pioneering.

Dr Zhu holds the position of a professor of Medicine at Harvard Medical School, director of Jiahui International Cancer Center, director of JIH Clinical Research.

Dr Xia has served as chief scientific officer of Adlai Nortye, the director of Translational Research Laboratory at Duke Cancer Institute and as an associate professor in the Department of Medicine, head of GSK Oncology Translational Research and chief scientific officer of Yangtze River Pharmaceutical Group Co Ltd.

The SAB will guide and advise the company as it advances its preclinical and clinical immuno-oncology programs to address unmet medical needs.



Related Headlines